Please login to the form below

Not currently logged in


This page shows the latest Amjevita news and features for those working in and with pharma, biotech and healthcare.

Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo

Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo

The Humira market is worth more than $15bn annually and, in addition to Boehringer's Cyltezo (adalimumab-adbm), other biosimilars that are set to launch in 2023 include Amgen’s Amjevita

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...